C4 Therapeutics, Inc. Logo

C4 Therapeutics, Inc.

Developing protein degrader medicines to treat cancer and other serious diseases.

CCCC | US

Overview

Corporate Details

ISIN(s):
US12529R1077
LEI:
Country:
United States of America
Address:
490 ARSENAL WAY, 2472 WATERTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on developing a new class of medicines through targeted protein degradation (TPD). The company's approach utilizes the body's natural protein disposal mechanisms to selectively eliminate disease-causing proteins. C4T leverages its proprietary TORPEDO® (Target Oriented Protein Degrader Optimizer) platform to design and advance a pipeline of small-molecule drug candidates aimed at treating cancer and other serious diseases. Its portfolio includes clinical programs such as Cemsidomide (CFT7455), CFT8919, and CFT1946.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all C4 Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for C4 Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for C4 Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea 475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan 4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom OCTHF

Talk to a Data Expert

Have a question? We'll get back to you promptly.